Cargando…
Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients
Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a membrane receptor in myeloid cells that mediates cellular phagocytosis and inflammation. TREM2 and its soluble extracellular domain are clearly implicated in neuroinflammation and neurodegeneration. sTREM2 is also expressed in atheroscler...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656572/ https://www.ncbi.nlm.nih.gov/pubmed/36361908 http://dx.doi.org/10.3390/ijms232113121 |
_version_ | 1784829469076226048 |
---|---|
author | Cuciuc, Valeri Tshori, Sagi Grib, Livi Sella, Gal Tuvali, Ortal Volodarsky, Igor Welt, Michael Fassler, Michael Shimoni, Sara George, Jacob |
author_facet | Cuciuc, Valeri Tshori, Sagi Grib, Livi Sella, Gal Tuvali, Ortal Volodarsky, Igor Welt, Michael Fassler, Michael Shimoni, Sara George, Jacob |
author_sort | Cuciuc, Valeri |
collection | PubMed |
description | Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a membrane receptor in myeloid cells that mediates cellular phagocytosis and inflammation. TREM2 and its soluble extracellular domain are clearly implicated in neuroinflammation and neurodegeneration. sTREM2 is also expressed in atherosclerotic macrophages. We hypothesized that sTREM2 would predict cardiovascular mortality in patients with established coronary atherosclerosis (CAD). Consecutive patients undergoing coronary angiography with the establishment of the diagnosis of CAD (n = 230) and without CAD (n = 53) were tested for their baseline serum sTREM2 levels. All patients were followed up for 84 months or until death occurred. sTREM2 correlated with age; however, no association was found between sTREM2 and the number of atherosclerotic vessels involved (p = 0.642). After 84 months of follow-up, 68 out of the 230 CAD patients had died. After adjusting for age and other risk factors, the adjusted hazard ratio for the highest quartile of sTREM2 was 2.37 (95% confidence interval 1.17–4.83) for death. In patients with established CAD, serum sTREM2 appears to predict cardiovascular death as a potential surrogate for plaque rupture. TREM2 and its soluble extracellular form might be implicated in the fate of the atherosclerotic plaque, but corroboration within larger studies is needed. |
format | Online Article Text |
id | pubmed-9656572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96565722022-11-15 Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients Cuciuc, Valeri Tshori, Sagi Grib, Livi Sella, Gal Tuvali, Ortal Volodarsky, Igor Welt, Michael Fassler, Michael Shimoni, Sara George, Jacob Int J Mol Sci Article Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is a membrane receptor in myeloid cells that mediates cellular phagocytosis and inflammation. TREM2 and its soluble extracellular domain are clearly implicated in neuroinflammation and neurodegeneration. sTREM2 is also expressed in atherosclerotic macrophages. We hypothesized that sTREM2 would predict cardiovascular mortality in patients with established coronary atherosclerosis (CAD). Consecutive patients undergoing coronary angiography with the establishment of the diagnosis of CAD (n = 230) and without CAD (n = 53) were tested for their baseline serum sTREM2 levels. All patients were followed up for 84 months or until death occurred. sTREM2 correlated with age; however, no association was found between sTREM2 and the number of atherosclerotic vessels involved (p = 0.642). After 84 months of follow-up, 68 out of the 230 CAD patients had died. After adjusting for age and other risk factors, the adjusted hazard ratio for the highest quartile of sTREM2 was 2.37 (95% confidence interval 1.17–4.83) for death. In patients with established CAD, serum sTREM2 appears to predict cardiovascular death as a potential surrogate for plaque rupture. TREM2 and its soluble extracellular form might be implicated in the fate of the atherosclerotic plaque, but corroboration within larger studies is needed. MDPI 2022-10-28 /pmc/articles/PMC9656572/ /pubmed/36361908 http://dx.doi.org/10.3390/ijms232113121 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cuciuc, Valeri Tshori, Sagi Grib, Livi Sella, Gal Tuvali, Ortal Volodarsky, Igor Welt, Michael Fassler, Michael Shimoni, Sara George, Jacob Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients |
title | Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients |
title_full | Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients |
title_fullStr | Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients |
title_full_unstemmed | Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients |
title_short | Circulating Soluble TREM2 and Cardiovascular Outcome in Cohort Study of Coronary Atherosclerosis Patients |
title_sort | circulating soluble trem2 and cardiovascular outcome in cohort study of coronary atherosclerosis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656572/ https://www.ncbi.nlm.nih.gov/pubmed/36361908 http://dx.doi.org/10.3390/ijms232113121 |
work_keys_str_mv | AT cuciucvaleri circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT tshorisagi circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT griblivi circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT sellagal circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT tuvaliortal circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT volodarskyigor circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT weltmichael circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT fasslermichael circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT shimonisara circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients AT georgejacob circulatingsolubletrem2andcardiovascularoutcomeincohortstudyofcoronaryatherosclerosispatients |